IRS Hopes GSK’s $3.4 Bil. Transfer Pricing Settlement Is Just The Beginning
Executive Summary
The Internal Revenue Service's multi-billion dollar settlement with GlaxoSmithKline over transfer pricing is a milestone for the agency in its efforts to better regulate the practice
You may also be interested in...
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
U.S. Drug Firms Under IRS Scrutiny For Offshore Income Shifting
U.S.-based drug companies inappropriately reported that foreign profits accounted for 66% of their worldwide profits in 2003-2005, 23% more than the amount calculated by Tax Analysts, according to a publication by the non-profit group